Title:Molecular Regulatory Roles of Long Non-coding RNA HOTTIP:
An Overview in Gastrointestinal Cancers
Volume: 22
Issue: 6
Author(s): Ummi Zulaiqha Hamid, Maw Shin Sim, Rhanye Mac Guad, Vetriselvan Subramaniyan, Mahendran Sekar, Neeraj Kumar Fuloria, Shivkanya Fuloria, Ker Woon Choy, Ismail Muhamad Fareez, Srinivasa Reddy Bonam and Yuan Seng Wu*
Affiliation:
- Centre for Virus and Vaccine Research, School of Medical
and Life Sciences, Sunway University, Selangor 47500, Malaysia
- Department of Biological Sciences,
School of Medical and Life Sciences, Sunway University, Selangor 47500, Malaysia
Keywords:
Molecular targets, lncRNA, HOTTIP, gastrointestinal cancer, cancer treatment, drug discovery.
Abstract: Gastrointestinal (GI) cancers presented an alarmingly high number of new
cancer cases worldwide and are highly characterised by poor prognosis. The poor
overall survival is mainly due to late detection and emerging challenges in treatment,
particularly chemoresistance. Thus, the identification of novel molecular targets in GI
cancer is highly regarded as the main focus. Recently, long non-coding RNAs (lncRNAs)
have been discovered as potential novel molecular targets for combating cancer, as they
are highly associated with carcinogenesis and have a great impact on cancer
progression. Amongst lncRNAs, HOTTIP has demonstrated a prominent oncogenic
regulation in cancer progression, particularly in GI cancers, including oesophageal
cancer, gastric cancer, hepatocellular carcinoma, pancreatic cancer, and colorectal
cancer. This review aimed to present a focused update on the regulatory roles of
HOTTIP in GI cancer progression and chemoresistance, as well as deciphering the
associated molecular mechanisms underlying their impact on cancer phenotypes and
chemoresistance and the key molecules involved. It has been reported that it regulates
the expression of various genes and proteins in GI cancers that impact cellular
functions, including proliferation, adhesion, migration and invasion, apoptosis,
chemosensitivity, and tumour differentiation. Furthermore, HOTTIP was also discovered
to have a higher diagnostic value as compared to existing diagnostic biomarkers.
Overall, HOTTIP has presented itself as a novel therapeutic target and potential
diagnostic biomarker in the development of GI cancer treatment.
